Albumedix Limited

Novozymes Biopharma Dk A/s

Novozymes Biopharma Dic A/s

Andrew Plumridge

Jason Cameron

Jan Terje Andersen

Esben Peter Friis

Inger Sandlie

Darrell Sleep

Karen Ann Delahay

Jens Erik Nielsen

Steven Athwal

Elizabeth Allan

Bjorn Dalhus

Leslie Evans

The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Albumin variants

The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.

Albumin derivatives and variants

Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.

Growing community of inventors

Derbyshire, United Kingdom

Andrew Plumridge